Skip to main content

Advertisement

SpringerLink
Log in

Lipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease

  • Review Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

The current epidemic affecting Indians is coronary artery disease (CAD), and is currently one of the most common causes of mortality and morbidity in developed and developing countries. The higher rate of CAD in Indians, as compared to people of other ethnic origin, may indicate a possible genetic susceptibility. Hence, Lp(a), an independent genetic risk marker for atherosclerosis and cardiovascular disease assumes great importance. Lp(a), an atherogenic lipoprotein, contains a cholesterol rich LDL particle, one molecule of apolipoprotein B-100 and a unique protein, apolipoprotein (a) which distinguishes it from LDL. Apo(a) is highly polymorphic and an inverse relationship between Lp(a) concentration and apo(a) isoform size has been observed. This is genetically controlled suggesting a functional diversity among the apo(a) isoforms. The LPA gene codes for apo(a) whose genetic heterogeneity is due to variations in its number of kringles. The exact pathogenic mechanism of Lp(a) is still not completely elucidated, but the structural homology of Lp(a) with LDL and plasmin is possibly responsible for its acting as a link between atherosclerosis and thrombosis. Upper limits of normal Lp(a) levels have not been defined for the Indian population. A cut off limit of 20 mg/dL has been suggested while for the Caucasian population it is 30 mg/dL. Though a variety of assays are available for its measurement, standardization of the analytical method is highly complicated as a majority of the methods are affected by the heterogeneity in apo(a) size. No therapeutic drug selectively targets Lp(a) but recently, new modifiers of apo(a) synthesis are being considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sekhri T, Kanwar RS, Wilfred R, Chigh P, Chillar M, Aggarwal R, et al. Prevalence of risk factors for coronary artery disease in an urban Indian population. BMJ Open. 2014;4:e005346. doi:10.1136/bmjopen-2014-005346.

  2. Bulatao RA, Stephens PW. Global estimates and projections of mortality by cause, 1970–2015. Preworking paper 1007. Washington: Population and Nutrition Department, World Bank 1992.

  3. Enas EA, Yusuf S, Mehta J. Meeting of international working group on coronary artery disease in South Asians. Indian Heart J. 1996;48:727–32.

    CAS  PubMed  Google Scholar 

  4. Rissam HS, Kishore S, Trehan N. Coronary artery disease in young Indians—the missing link. J Indian Acad Clin Med. 2001;2(3):128–31.

    Google Scholar 

  5. Negus BH, Williard JE, Glamam DB, Landau C, Snyder RW 2nd, Hillis LD, et al. Coronary anatomy and prognosis of young asymptomatic survivors of myocardial infarction. Am J Med. 1994;96:354–8.

    Article  CAS  PubMed  Google Scholar 

  6. Mammi MVI, Pavithran P, Rahman PA, Pisharody R, Sugathan K. Acute MI in North Kerala. A 20 years hospital based study. Indian Heart J. 1991;43:93–6.

    CAS  PubMed  Google Scholar 

  7. Maher VM, Brown BG, Marcovina SM, Hilger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein (a). JAMA. 1995;274:1771–4.

    Article  CAS  PubMed  Google Scholar 

  8. Foody JM, Milberg JA, Robinson K, Pearce GL, Jacobson DW, Sprecher DL. Homocysteine and lipoprotein (a) interact to increase CAD risk in young men and women. Arterioscler Thromb Vasc Biol. 2000;20:493–9.

    Article  CAS  PubMed  Google Scholar 

  9. Hobbs HH, White AL. Lipoprotein (a): intrigues and insights. Curr Opin Lipidol. 1999;10:225–36.

    Article  CAS  PubMed  Google Scholar 

  10. Utterman G. Genetic architecture and evolution of the lipoprotein (a) trait. Curr Opin Lipidol. 1999;10:133–41.

    Article  Google Scholar 

  11. Uttermann G. Lipoprotein (a). In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw Hill; 2001. p. 2753–87.

    Google Scholar 

  12. Enas EA, Garg A, Davidson MA, Nair VM, Huet BA, Yusuf S. Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. Indian Heart J. 1996;48:343–53.

    CAS  PubMed  Google Scholar 

  13. Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M, et al. Lipoprotein (a) levels and risk of future coronary heart disease: large scale prospective data. Arch Intern Med. 2008;168:598–608.

    Article  CAS  PubMed  Google Scholar 

  14. McCormick SP. Lipoprotein (a): biology and clinical importance. Clin Biochem Rev. 2004;25:69–80.

    PubMed Central  PubMed  Google Scholar 

  15. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein (a), hormone replacement therapy, and the risk of future cardiovascular events. J Am Coll Cardiol. 2008;52:124–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Cantin B, Gagnon F, Moorjani S, Despres JP, Lamarche B, Lupien PJ, et al. Is lipoprotein (a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol. 1998;31:519–25.

    Article  CAS  PubMed  Google Scholar 

  17. Suk DJ, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular event among initially healthy women. JAMA. 2006;296:1363–70.

    Article  Google Scholar 

  18. Albers JJ, Marcoina SM, Lodge MS. The unique lipoprotein (a): properties and immunochemical measurement. Clin Chem. 1990;36:2019–26.

    CAS  PubMed  Google Scholar 

  19. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ. 1990;301:1248–51.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Ornek E, Murat S, Duran M, Turfan M, Kurtul A, Demircelik MB, et al. The relationship between lipoprotein (a) and coronary artery disease, as well as its variable nature following myocardial infarction. Clin Investig Med. 2011;34(1):E14–20.

    CAS  Google Scholar 

  21. Gambhir JK, Kaur H, Gambhir DS, Prabhu KM. Lipoprotein(a) as an independent risk factor for coronary artery disease in patients below 40 years of age. Indian Heart J. 2000;4:411–5.

    Google Scholar 

  22. Luthra K, Vasisht S, Chhabra S, Raju KR, Agarwal DP, Manchanda SC, et al. LP (a) phenotypes and levels in angiographically proven coronary heart disease patients and controls. Indian J Clin Biochem. 1998;13(1):12–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Vasisht S, Gulati R, Srivastava LM, Narang R, Chopra V, Srivastava N, et al. Apolipoprotein(a) polymorphism and its association with plasma lipoprotein(a) levels: a North Indian Study. Indian Heart J. 2005;2:407–10.

    Google Scholar 

  24. Mohan V, Deepa R, Rema M. Lipoprotein (a) and coronary artery disease in Indians. JAPI. 1998;46:979–80.

    CAS  PubMed  Google Scholar 

  25. Geethanjali FS, Luthra K, Lingerhel A, Kanagasabapathy AS, Jacob J, Srivastava LM, et al. Analysis of the apo (a) size polymorphism in Asian Indian populations: association with Lp(a) concentration and coronary heart disease. Atherosclerosis. 2003;169:121–30.

    Article  CAS  PubMed  Google Scholar 

  26. Gupta R, Kastia S, Rastogi S, Kaul V, Nagar R, Enas EA. Lipoprotein(a) in coronary heart disease: a case-control study. Indian Heart J. 2002;52:407–10.

    Google Scholar 

  27. Vasisht S, Agarwal DP, Wasir HS, Srivastava LM. Lipoprotein (a) levels in alcohol drinking and alcohol non-drinking coronary artery disease patients. Indian J Clin Biochem. 1996;11:176–9.

    Article  Google Scholar 

  28. Anand SS, Yusuf S, Vuksan V, Devanesen S, Teo KK, Montague PA, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in ethnic groups (SHARE). Lancet. 2002;356(9226):279–84.

    Article  Google Scholar 

  29. Low PS, Heng CK, Saha N, Tay JSH. Racial variation of cord plasma lipoprotein (a) level in relation to coronary risk level: a study in three ethnic groups in Singapore. Pediatr Res. 1996;40(5):718–22.

    Article  CAS  PubMed  Google Scholar 

  30. Anand SS, Enas EA, Pogue J, Haffner S, Pearson T, Yusuf S. Elevated lipoprotein(a) level in South Asians in North America. Metabolism. 1998;47(2):182–4.

    Article  CAS  PubMed  Google Scholar 

  31. Tavridou A, Unwin N, Bhopal R, Laker MF. Predictors of lipoprotein (a) level in a European and South Asian population in the Newcastle Heart Project. Eur J Clin Investig. 2003;33(8):686–92.

    Article  CAS  Google Scholar 

  32. Rajasekhar D, Saibaba KSS, Srinivasa Rao PVLN, Latheef SAA, Subramanyam G. Lipoprotein(a): better assessor of coronary heart disease risk in South Indian population. Indian J Clin Biochem. 2004;19(2):53–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Pedreno J, Fernandez R, Ballester A, Jornet A, Uson M, Camela J, et al. Lack of association with serum Lp(a) with Type 2 Diabetes Mellitus in patients with angiographically defined coronary artery disease. Int J Cardiol. 2000;79:159–67.

    Article  Google Scholar 

  34. Wong MS, Chew WL, Aw TC. Serum lipoprotein (a) profiles in Singaporean population. Pathology. 1999;31:225–9.

    Article  CAS  PubMed  Google Scholar 

  35. Henrikson P, Angelin P, Berglund L. Hormonal regulation of serum Lp(a) levels: opposite effects after oestrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Investig. 1992;89:1166–71.

    Article  Google Scholar 

  36. Enas EA, Dhawan J, Petkar S. Coronary Artery Disease in Asian Indians: Lessons learned so far and the role of Lp(a). Ind Heart J. 1997;49:25–34.

    CAS  Google Scholar 

  37. Gupta R, Gupta VP. Meta-analysis of coronary heart disease prevalence in India. Indian Heart J. 1996;48:241–5.

    CAS  PubMed  Google Scholar 

  38. Durrington PN, Ishola M, Hunt L, Arrol S, Bhatnagar D. Apolipoprotein(a), A1 and B and parental history in men with early onset ischemic heart disease. Lancet. 1998;1:1070–3.

    Google Scholar 

  39. Schaefer EJ, Lamon-Fava S, Jenner JL, Mcnamara JR, Ordovas JM, Davis CE, et al. Lipoprotein (a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 1994;271:999–1003.

    Article  CAS  PubMed  Google Scholar 

  40. Mohan V, Deepa R, Haranath SP, Premalatha G, Rema M, Sastry NG, et al. Lipoprotein (a) is an independent risk factor for coronary artery disease in NIDDM patients in South India. Diabetes Care. 1998;21:1819–23.

    Article  CAS  PubMed  Google Scholar 

  41. Angles-Cano E. Structural basis for the pathophysiology of lipoprotein (a) in the athero-thrombotic process. Braz J Med Biol Res. 1997;30:1271–80.

    Article  CAS  PubMed  Google Scholar 

  42. Neilsen LB. Atherogenicity of lipoprotein (a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. Atherosclerosis. 1999;143:229–43.

    Article  Google Scholar 

  43. Kojima S, Harpel PC, Rifkin D. Lipoprotein (a) inhibits the generation of transforming growth factor β: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol. 1991;113:1439–45.

    Article  CAS  PubMed  Google Scholar 

  44. Luthra K, Misra A, Srivastava LM. Lipoprotein (a): biology and role in atherosclerotic vascular diseases. Curr Sci. 1999;76:1553–60.

    CAS  Google Scholar 

  45. Marcovina SM, Koschinsky ML, Albers JJ, Scarlatos S. Report of the national heart, lung and blood institute workshop on lipoprotein (a) and cardiovascular disease: recent advances and future directions. Clin Chem. 2003;49:1785–96.

    Article  CAS  PubMed  Google Scholar 

  46. Koschinsky M, Marcovina SM. Lipoprotein (a). In: Ballantyne C, editor. Clinical lipidology: a companion to Braunwald’s heart disease. Philadelphia: Saunders Elselvier; 2009. p. 130–43.

    Chapter  Google Scholar 

  47. McLean J, Tomlinson J, Kuang W, Eaton D, Chen E, Fless G, et al. cDna sequence of human apololipoprotein(a) is homologous to plasminogen. Nature. 1978;330:132–7.

    Article  Google Scholar 

  48. Eaton D, Fless GM, Kohr W, McLean J, Xu Q, Miller C, et al. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA. 1987;84:3224–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Guevara J, Knapp RD, Honda S, Northup SR, Morrisett JD. A structural assessment of the apo (a) protein of human lipoprotein (a). Proteins. 1992;12:188–99.

    Article  CAS  PubMed  Google Scholar 

  50. Kambon MI, Ferrell RE, Kottke BA. Expressed hypervariable polymorphism of apolipoprotein(a). Am J Hum Genet. 1991;49:1063–74.

    Google Scholar 

  51. Lackner G, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Investig. 1991;87:2153–61.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Kraft HG, Lingenhel A, Kochi S, Hoppichler F, Kronenberg F, Abe A, et al. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vacs Biol. 1996;16(6):713–9.

    Article  CAS  Google Scholar 

  53. Holmer SR, Hengstenberg C, Kraft HG, Mayer B, Pöll M, Kürzinger S, et al. Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infraction. Circulation. 2003;107(5):696–701.

    Article  PubMed  Google Scholar 

  54. UtermannG G, Kraft HG, Menzel H, Hopferweiser T, Seitz C. Genetics of the quantitative Lp(a) lipoprotein trait I. Relation of Lp(a) glycoprotein phenotypes to Lp(a) lipoprotein concentrations in plasma. Hum Genet. 1998;7:41–6.

    Google Scholar 

  55. Uutermann G, Duba C, Menzel H. Genetics of the quantitative Lp(a) lipoprotein trait II.Inheritance of Lp(a) glycoprotein phenotypes. Hum Genet. 1998;78:47–50.

    Article  Google Scholar 

  56. Molgaard J, Klasusen IC, Lassvik C, Faergeman O, Gerdes LU, Olsson AG. Significant association between low-molecular-weight apolipoprotein (a) isoform and intermittent claudication. Arterioscler Thromb. 1992;12:895–901.

    Article  CAS  PubMed  Google Scholar 

  57. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, et al. Relation of serum lipoprotein (a) and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 1990;322:1494–9.

    Article  CAS  PubMed  Google Scholar 

  58. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, et al. Apo(a) isoform predict risk for coronary heart disease. A study in six populations. Arterioscl Thromb. 1992;12:1214–26.

    Article  CAS  PubMed  Google Scholar 

  59. Hervio L, Chapman MJ, Thilet J, Loyau S, Angles-Cano E. Does apolipoprotein (a) heterogeneity influence lipoprotein (a) effect on fibrinolysis? Blood. 1993;82:392–7.

    CAS  PubMed  Google Scholar 

  60. Rouy D, Grailhe P, Chapman J, Angles-Cano E. Lipoprotein (a) impairs generation of plasmin by fibrin bound tissue-type plasminogen activator. Arterioscl and Thromb. 1991;11:629–38.

    Article  CAS  Google Scholar 

  61. Tsimikas S, Hall JL. Lipoprotein (a) as a potential causal genetic risk factor of cardiovascular disease. J Am Coll Cardiol. 2012;60:716–21.

    Article  CAS  PubMed  Google Scholar 

  62. Cantin B, Despres JP, Lamarche B, Moorjani S, Lupien PJ, Bogaty P, et al. Association of fibrinogen and lipoprotein (a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). Am J Cardiol. 2002;89(6):662–6.

    Article  CAS  PubMed  Google Scholar 

  63. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210:353–61.

    Article  CAS  PubMed  Google Scholar 

  64. Carlson LA, Rosenhamer G. Reduction in mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;233:405–18.

    Google Scholar 

  65. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: long term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–55.

    Article  CAS  PubMed  Google Scholar 

  66. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 1990;264:3013–7.

    Article  CAS  PubMed  Google Scholar 

  67. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289–98.

    Article  CAS  PubMed  Google Scholar 

  68. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113–22.

    Article  CAS  PubMed  Google Scholar 

  69. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010;126:314–45.

    Article  CAS  PubMed  Google Scholar 

  70. Tziomalos K, Athyros VG, Wierzbicki AS, Mikhailidis DP. Lipoprotein(a): where are we now? Curr Opin Cardiol. 2009;24:351–7.

    Article  PubMed  Google Scholar 

  71. Gonbert S, Malinsky S, Sposito AC, Laouenan H, Doucet C, Chapman MJ, et al. Atorvastatin lowers lipoprotein (a) but not apolipoprotein (a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis. 2002;164:305–11.

    Article  CAS  PubMed  Google Scholar 

  72. Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198:247–55.

    Article  CAS  PubMed  Google Scholar 

  73. Koschinsky ML, Marcovina SM. Structure—function relationship in apolipoprotein(a): insight into lipoprotein (a) assembly and pathogenicity. Curr Opin Lipidol. 2004;15:167–74.

    Article  CAS  PubMed  Google Scholar 

  74. Merki E, Graham MJ, Mullick AE, Miller ER, Crooke RM, Pitas RE, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein (a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation. 2008;118:743–53.

    Article  CAS  PubMed  Google Scholar 

  75. Ladenson PW, Kristensen JD, Ridgway EC, Oisson AG, Carlsson B, Klein I, et al. Use of the thyroid hormone analogue eprotirome in statin treated dyslipidemia. N Engl J Med. 2010;362:906–16.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, Sir Ganga Ram Hospital, Rajender Nagar, New Delhi, 110060, India

    Anjali Manocha & L. M. Srivastava

Authors
  1. Anjali Manocha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. M. Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. M. Srivastava.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Manocha, A., Srivastava, L.M. Lipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease. Ind J Clin Biochem 31, 13–20 (2016). https://doi.org/10.1007/s12291-015-0483-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-015-0483-3

Keywords

Search

Navigation